Retrospective Analysis of Blood Biomarkers of Neurological Injury in Human Cases of

2 Viral Infection and Bacterial Sepsis

- 3 Maggie L. Bartlett^{1,2}, Heather Goux^{1,2}, Linwood Johnson^{1,2}, Kevin L. Schully³, Melissa
- 4 Gregory⁴, Jost Brandsma⁴, Josh G. Chenoweth⁴, Danielle V. Clark⁴, Luis Felipe Rivera^{7,8},
- 5 Carlos Lezcano-Coba^{7,8}, Amy Y. Vittor⁵, Ronald Hayes⁶, Josefrancisco Galué^{7,8}, Jean-Paul
- 6 Carrera^{7,8,9}, Darci R. Smith¹

1

- 8 ¹Naval Medical Research Command, Biological Defense Research Directorate, Microbiology
- 9 and Immunology Department; Ft. Detrick, MD, ²Parsons Corporation, Health and Biosciences;
- 10 Centreville, VA, ³Naval Medical Research Command, Biological Defense Research Directorate,
- 11 ACESO Department; Ft. Detrick, MD, ⁴The Austere environments Consortium for Enhanced
- 12 Sepsis Outcomes, The Henry M. Jackson Foundation for the Advancement of Military Medicine
- Inc., Bethesda, MD, ⁵University of Florida, Department of Medicine; Gainesville, FL, ⁶Banyan
- Biomarkers, ⁷Gorgas Memorial Institute, Panama City, Panama, ⁸Carson Centre for Research in
- Environment and Emerging Infectious Diseases, La Peñita, Darién, Panama, ⁹Department of
- 16 Biology, University of Oxford, Oxford, United Kingdom,
- 17 Corresponding author: Darci R. Smith darci.smith.civ@health.mil
- 18 Abstract:
- 19 **Background.** Blood biomarkers of neurological injury could provide a rapid diagnosis of central
- 20 nervous system (CNS) injury caused by infections. An FDA-approved assay for mild traumatic
- brain injury (TBI) measures glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal
- 22 hydrolase L1 (UCH-L1), which signal astrocyte and neuronal injury, respectively. Here, we
- assessed the applicability of this biomarker assay for determining infection-induced brain injury.

Methods. We measured serum levels of GFAP and UCH-L1 retrospectively in serum samples 24 from three study populations: 1) human cases infected with Venezuelan equine encephalitis virus 25 (VEEV) and Madariaga virus (MADV) (n = 73), 2) human sepsis patients who were severely ill 26 or diagnosed with encephalitis (n = 66), and 3) sepsis cases that were subsequently evaluated for 27 cognitive impairment (n = 64). 28 **Results.** In the virus infection group, we found elevated GFAP for VEEV (p = 0.014) and 29 MADV (p = 0.011) infections, which correlated with seizures (p = 0.006). In the bacterial sepsis 30 group, GFAP was elevated in cases diagnosed with encephalitis (p = 0.0007) and correlated with 31 32 headaches (p = 0.0002). In the bacterial sepsis cases with a later cognitive assessment, elevated GFAP (p = 0.0057) at study enrollment was associated with cognitive impairment six months 33 later with a positive prognostic capacity of 79% (CI: 66-95%; p = 0.0068). 34 35 *Conclusions*. GFAP and UCH-L1 levels measured using an FDA-approved assay for TBI may indicate brain injury resulting from viral or bacterial infections and could predict the 36 development of neurological sequelae. 37 **Keywords**: Six words → Viruses, encephalitis, biomarkers, GFAP, UCH-L1, sepsis 38

Article word count (Background through Discussion): 3,006

Background

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

Central nervous system (CNS) infections, which can lead to brain injury via invasion of brain tissue, inflammation, and/or the release of toxins, can be diagnostically challenging (1). Diagnosis requires a combination of clinical assessment, magnetic resonance imaging (MRI) studies and computed tomography (CT) scans, cerebrospinal fluid (CSF) analysis, and identification of the causative pathogen. Neurological injury biomarkers could provide a new approach to the diagnosis of infection-induced CNS injury. The first FDA-approved test for a blood biomarker for acute traumatic brain injury (TBI) detects glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), which signal astrocyte and neuronal injury, respectively (2). GFAP and UCH-L1 are also used as biomarkers for neurodegenerative diseases in blood or CSF, like multiple sclerosis (3, 4), neuromyelitis optica spectrum disorder (5), Alzheimer's disease (6-8), and less often for CNS infections (9, 10). Venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and Madariaga virus (MADV) are important mosquito-borne, single-stranded positive-sense RNA viruses (Togaviridae; Alphavirus) that circulate throughout the Americas and infect the CNS of humans and equids (11). VEEV enzootic/endemic subtype ID infection is prevalent in the eastern province of Darién, Panama, with seroprevalence up to 75% in some villages(11). EEEV was reclassified as two different species in 2010: EEEV in North America and MADV in Latin America (12). MADV was not associated with human outbreaks until 2010 when the first human MADV outbreak was reported in Darién, Panama (13). A force-of-infection model applied to two serosurveys from Darién Province in 2012 and 2017 found endemic alphavirus transmission (14). Alphavirus disease typically presents as a self-limited febrile illness but can be fatal, and persistent neurological symptoms have occurred for up to five years following MADV

or VEEV exposure (11).

Sepsis, including septicemia, pneumonia, skin infections, and intra-abdominal infections, is a serious and potentially life-threatening consequence of the exaggerated release of cytokines and other inflammatory mediators in response to infection. The inflammatory response leads to cellular injury and organ dysfunction, including the CNS (15). Although bacteria can cause meningitis and brain abscesses, CNS injury may result indirectly from cytokine-mediated alterations in the blood-brain barrier (BBB), hypoxia, and microcirculatory abnormalities (13). Sepsis-associated encephalopathy affects about 30% of patients with sepsis and is characterized by an altered level of consciousness (16). Sepsis patients who recover often suffer long-term cognitive impairment resulting from BBB disruption, neuroinflammation, neurotransmitter dysfunction, and neuronal loss (17, 18).

Here, we determined the efficacy of an FDA-approved Brain Trauma Indicator (BTI) biomarker assay, designed for brain injury in mild TBI patients (2), in detecting brain injury caused by infections. The three study populations we evaluated included acute alphavirus cases, sepsis cases, and sepsis cases that were evaluated after recovery for cognitive impairment (Table 1). We measured higher levels of GFAP in all cohorts compared to uninfected controls, suggesting that GFAP is a good indicator of infection-induced brain injury and may predict neurological sequelae, such as cognitive impairment. This is the first report that supports the use of an FDA-approved blood-based biomarker assay to detect possible neurological injury in viral and bacterial infections.

Methods

- **Study Populations and Sample Collection Procedures**
- 85 Study Population 1: virus infection group

Sera and metadata were collected from consenting adults and children with parental consent during an acute alphaviral outbreak in 2018-2019 in Aruza, Darién, by the Gorgas Memorial Institute, with negative control serum samples collected from healthy individuals in the region. Sera were deidentified and shipped on dry ice to the Naval Medical Research Command (NMRC). The studies were approved by the Panamanian Ministry of Health (protocol: 2077), the Gorgas Institutional Review Board (IRB) (protocol: 335/CBI/ICGES/21), and the University of Florida IRB (protocol: 201500292).

Enzyme-linked immunosorbent assays (ELISAs) were used to measure IgM and IgG antibodies to MADV and VEEV and samples were run in duplicate. ELISA antigens were prepared from the EEEV (prepared by Dr. Robert Shope at the Yale Arbovirus Research Unit in August 1989) and VEEV complex strain 78V-3531 (from an infected mouse brain) (11). All samples were also tested for viruses using virus-specific plaque reduction neutralization tests (PRNTs). A positive sample was reported as the reciprocal of the highest dilution that reduced plaque counts by >80% (PRNT₈₀). Reactivity to VEEV (strain TC-83) and MADV (strain GML-267113, isolated from a fatal human case in Panama in 2017) was measured (14).

Study population 2: bacterial sepsis

Sera from suspected human sepsis cases were collected by NMRC's Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO) program during prospective observational studies in Cambodia and Ghana (19, 20) under IRB-approved protocols (protocols: NMRC.2013.0019 and NMRC.2016.0004-GHA) in compliance with all applicable U.S. Federal regulations governing the protection of human subjects. All subjects, or their legally authorized representatives, provided written informed consent and authorized future use of their specimens and data. Responses were recorded on a standardized case report form and included

demographics, medical history, physical exam findings, and admitting diagnosis. A diagnosis of a CNS infection was based on the judgment of two physicians. If these two physicians did not agree on a diagnosis, a third physician reviewed patient records and made the diagnosis. Other infections were confirmed by culture or polymerases chain reaction (PCR) (supplementary data 1) and included respiratory tract infection, bacteremia, abscess, cellulitis, gastrointestinal tract infection, fungemia, oral cavity infection, reproductive tract infection, or cardiovascular infection (20).

Study population 3: bacterial sepsis with cognitive assessment

Sera from human sepsis cases were collected by the NMRC ACESO program during prospective observational studies in Ghana as described above for study population 2. Sera were collected at enrollment (day 0; n = 64) or day 28 after enrollment (day 28; n = 38). Impairment was assessed using the Montreal Cognitive Assessment Basic (MoCA-B) (21) for individuals at enrollment (n = 64), upon discharge (n = 64), day 28 (n = 38), and months 6 (n = 32) and 12 (n = 20) after discharge, as available.

GFAP and UCH-L1 Assays

Sera was evaluated with the Banyan BTI assay according to the manufacturer's guidelines. Antibodies were vortexed, diluted in antibody diluent, and kit standards prepared following a serial dilution (UCH-L1: 2,560 pg/mL to 80 pg/mL; GFAP 320 pg/mL to 10 pg/mL). Serum was added to plates (UCH-L1: 25 μ L; GFAP: 50 μ L) in duplicate and incubated for 60 minutes at 37 °C with shaking at 500 rpm. Plates were washed, detection antibody added and allowed to incubate for 60 minutes at 37 °C while shaking at 500 rpm. Plates were washed and 150 μ L of substrate added per well prior to reading optical density at 225 nm. If the concentration exceeded the upper limit of quantitation, serum was diluted and re-run. Samples that were below the lower

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

limit of quantitation (LLOQ) were included at half the minimum LLOQ for statistical analyses. The cutoff for positivity for mild TBI in the BTI assay is 327 pg/mL UCH-L1 and 22 pg/mL GFAP. **Statistical Analyses** Statistical analyses were performed using SPSS (Version 19.0. Armonk, NY: IBM Corp) or GraphPad v9 and included the Mann-Whitney U test following normality testing, the Jonckheere-Terpstra (JT) test, and area under the curve plots. A chi-square test was used to determine statistical significance for age and sex differences. The relevant tests are indicated in figure legends. **Results Study Population 1: Virus Infection** For population 1, serum samples were collected from 33 cases of acute alphavirus infection in eastern Panama. Subjects with confirmed infections tested positive for VEEV, MADV, or both by IgM ELISA and PRNT (Supplemental Table 1), whereas subjects with likely infection tested positive for either IgM ELISA or PRNT. Symptoms consistent with alphavirus illness included fever, chills, headaches, and, less commonly, myalgia, arthralgia, nausea, vomiting, and seizures (Figure 1A, Table 2). Patients infected with MADV had a higher incidence of seizures (37.5%) compared to those infected with VEEV ID (5.0%), and the only fatality occurred in an individual with MADV. Serum levels of GFAP and UCH-L1 were determined with the BTI assay for uninfected controls and the alphavirus-positive individuals. Mean UCH-L1 levels were significantly lower in cases of VEEV but not in cases of MADV, whereas the mean GFAP levels

were significantly higher for subjects with either alphavirus (Figure 1B). However, UCH-L1 was

elevated in the fatal case and in two out of the four cases with seizures. The highest levels of GFAP were observed in three of the four cases with seizures and the fatal case. When grouped by time since onset of fever (early 0–7 days, mid 8–14 days, or late >15 days), UCH-LI decreased (p = 0.00031) during the mid-timeframe and was statistically unchanged either early or late (Figure 1C). However, GFAP was elevated at the early (p = 0.013) and mid (p = 0.0059) timeframes but not late (p = 0.092) (Figure 1C), which may be due to the small sample size at this time point. For symptoms, seizures were significantly associated with higher levels of GFAP (p = 0.006) (Table 2). Interestingly, GFAP levels were higher in those without inflammatory response symptoms, including fever, chills, and myalgia, and this increase was statistically significant for chills (p = 0.023). There were no significant associations between levels of UCH-L1 and symptoms. A Wilcoxon rank-sum analysis indicated that the relationship between GFAP and acute alphavirus infection, i.e., infection with both VEEV and MADV, acute MADV infection, or acute VEEV infection was strengthened, while the relationship between UCH-L1 and any infection remained unchanged (Supplemental Table 2). These results suggest that GFAP may be a promising biomarker of acute alphavirus disease and may indicate disease severity.

Study Population 2: Bacterial Sepsis

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

We analyzed patient samples from sepsis studies completed in Cambodia (20) and Ghana (19) to measure changes in UCH-L1 or GFAP as a result of bacterial infection. This study population was comprised of 53 severely ill, hospitalized patients who presented with at least two systemic inflammatory response syndrome criteria and a suspected infection. These included a sepsis cohort with symptoms consistent with CNS disease (n = 21) and individuals without symptoms of CNS disease but positive for infection (n = 32). A control group (n = 13) comprised healthy

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

individuals from the same region. A diagnosis of a CNS infection was determined after a review by two physicians of the patient's medical history, which included evaluation for nerve palsies, paralysis, reflex response abnormalities, and assessment by the Glasgow coma scale. The severely ill patients presented with fever, headache, abdominal pain, nausea, and diarrhea (Figure 2A). This cohort reported more myalgia than the alphavirus cohort; however, there was no difference in myalgia between CNS and other infections. Serum levels of GFAP and UCH-L1 were determined with the BTI assay for control samples, the severely ill individuals with no signs of a CNS infection, and those diagnosed with a CNS infection. We found no significant differences in UCH-L1 levels; however, GFAP levels were significantly higher in individuals with CNS infections and elevated, although not significantly, in patients with non-CNS infections (Figure 2B). Also, patients with fatal vs. non-fatal cases had similar levels of UCH-L1 and GFAP. Among symptoms, headache was positively associated with GFAP (p = 0.0002) but negatively associated with UCH-L1 (p < 0.0001) (Table 3). These results are similar to those for our viral infection study population (group 1) and indicate that elevated levels of GFAP may be a potential biomarker to indicate CNS infection. Study Population 3: Bacterial Sepsis with Cognitive Assessment Finally, we determined whether the levels of these biomarkers measured at study enrollment would predict cognitive impairment after sepsis based on MoCA-B scores, which were measured during study enrollment and on subsequent visits up to a year later. MoCA-B scoring differentiates among cognitive syndromes by assessing memory, executive function, attention, language, visuospatial parameters, and orientation (21). A normal score is \geq 26, whereas impairment falls into mild (18–25), moderate (10–17), and severe (< 10) categories. Previous

sepsis studies completed in Ghana (19) provided serum samples collected prospectively from

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

hospitalized cases of sepsis at study enrollment (day 0) and day 28 after enrollment. MoCA-B scores were determined for individuals at study enrollment, upon discharge, on day 28, and 6 and 12 months after discharge, when feasible. Levels of UCH-L1 and GFAP were measured in individuals at study enrollment (day 0) and day 28 after enrollment. Mean UCH-L1 levels were unchanged, whereas the mean GFAP levels were significantly higher at both time points (Figure 3A). We then evaluated the levels of GFAP and UCH-L1 at study enrollment (day 0) stratified by the average MoCA score after discharge and up to 12 months later. Levels of UCH-L1 trended higher in cases with severe cognitive impairment and persisted up to 12 months after symptom onset; however, they did not reach statistical significance (Figure 3B). Levels of GFAP in serum at study enrollment increased with increasing levels of cognitive impairment vs. controls up to twelve months after study enrollment (Figure 3B). The percentage of individuals who developed cognitive impairment after discharge from the hospital was compared to the results of the BTI assay at study enrollment (Table 4). Individuals with a higher level of cognitive impairment after discharge were more likely to have had a positive BTI assay at study enrollment. Thus, the Banyan BTI assay may predict the development of reduced cognitive function after infection. Supporting these associations, trends for UCH-L1 (p = 0.00363) and GFAP ($p = 1.849 \times 10^{-8}$) were significant by the JT test for ranked categories. Thus, serum GFAP levels at study enrollment predicted cognitive impairment as measured by MoCA-B scores at six months. The six-month time point was chosen for comparison because the sample size was split equally between patients with normal (≥26) or impaired (<26) MoCA-B scores. Not only was cognitive impairment associated with higher levels of GFAP at enrollment (p = 0.0057), but this metric should identify 79% (CI: 66–95%; p=0.0068) of cases correctly based on time-dependent receiver operating characteristic (ROC) curves (Figure 3C and Figure 3D).

Therefore, GFAP levels may serve as an effective biomarker for predicting the development of cognitive impairment in individuals with severe infectious diseases.

Discussion

We evaluated two brain biomarkers using an FDA-approved BTI assay developed originally for acute TBI, in which elevation of either or both biomarkers are considered indicative of brain injury (2). GFAP is an intermediate filament protein expressed almost exclusively in astrocytes, where it is induced by neural injury and released upon disintegration of the astrocyte cytoskeleton (22). UCH-L1 is expressed only in neurons where it is involved in the ubiquitination of proteins intended for degradation by the proteasomal pathway and plays an important role in the removal of oxidized or misfolded proteins in both normal and pathological conditions (8). Analyzing both GFAP and UCH-L1 may reflect distinct causes of brain injury. In severe TBI, focal mass lesions cause an increase in GFAP, whereas diffuse brain injuries cause an increase in UCH-L1 (23, 24). Here, we found a significant increase in GFAP, but not UCH-L1, in the alphavirus and sepsis cohorts, suggesting that GFAP is a shared biomarker for brain injury and infectious diseases of the CNS.

Previous work on biomarkers, including GFAP, analyzed only the CSF, not serum from viral encephalitis cases, and none used an FDA-approved assay (25-30). Early identification of sepsis-associated encephalopathy, one of the most serious clinical manifestations of sepsis (31), would provide a more accurate diagnosis and prognosis, which now relies on nonspecific clinical manifestations and imaging features, often followed by lumbar punctures and electroencephalograms. Several biomarkers have been proposed for the rapid detection of sepsis-related brain injury (32), including serum GFAP and UCH-L1, which correlate with the occurrence, severity, and prognosis of sepsis-associated encephalopathy (33, 34). We found

higher levels of GFAP in acute CNS-involved sepsis, and these higher levels of serum GFAP at the time of hospitalization correlated with cognitive decline up to twelve months after symptom onset in our group 3 cohort. We also observed elevated UCH-L1, similar to the previous study (33), but it was not statistically significant, which may be due to the sample size or time of sampling. Therefore, GFAP and possibly UCH-L1 may serve as biomarkers for sepsis-related brain injury and should be further evaluated.

Lesions in the brain of fatal human VEEV cases appear to result from injury due to virus replication and clearance of infected cells by the immune system (35). Although neurons are the primary targets of encephalitic alphaviruses and viral cytopathology is important in CNS dysfunction, fatal encephalitis is likely mediated by the immune response to infection rather than direct virus replication (36). For individuals infected by the encephalitic alphaviruses, mean levels of GFAP and the incidence of seizures were significantly higher than controls, whereas the mean UCH-L1 levels were reduced significantly in VEEV but not MADV. The latter results were unexpected because neurons are the major target cells of the encephalitic alphaviruses, but these results may be due to the time of sampling. In cell culture and animal models, encephalitic alphaviruses also infect astrocytes (37-39), which are immuno-activated in infected animals (36). Our GFAP results likely indicate that astrocytes were injured by virus infection or the immune response.

Our results suggests that GFAP levels may serve as an effective biomarker for predicting the development of cognitive impairment in individuals with severe infectious diseases.

Neurological sequelae after recovery from alphavirus infection occurs frequently and includes seizures, paralysis, intellectual disability, behavioral changes, photophobia, coma, or visual disturbances (11, 40). GFAP may predict the development of neurologic sequelae after

alphavirus infection, similar to our results with the bacterial sepsis cohort, and is a focus of our future studies.

In conclusion, CNS infections have high rates of morbidity and mortality and blood-based diagnostic assays for brain injury could aid clinicians when deciding whether imaging is needed and to initiate treatment. Our data support the use of the BTI assay to identify brain injury caused by CNS infection that could lead to neurological sequelae. Further research is needed to identify the relevant timeframes, examine additional cohorts, and conduct clinical trials to determine the impact of this assay on patient outcomes. Our study lays the foundation for these efforts.

Tables

Table 1. Study populations for neurological injury biomarker assessment

| Group | Subgroup | Serum (N) | Country | Reference |
|--|--------------------------|-----------|------------------------------|-----------|
| 1—Virus Infection | Acute MADV | 8 | Panama | N/A |
| | Acute VEEV | 22 | | |
| | Both (MADV/VEEV) | 3 | | |
| | Controls 1 | 40 | 1 | |
| 2—Bacterial Infection (Sepsis) | CNS Infection | 21 | Ghana n=10, Cambodia n=11 | 20, 21 |
| | Other Infection | 32 | Ghana n=14, Cambodia n=18 | |
| | Controls ² | 13 | Ghana | 21 |
| 3—Bacterial Infection (Sepsis with Cognitive Assessment) | Study Enrollment (day 0) | 64 | Ghana | 21 |
| | 28 Days Post Enrollment | 38 | | |

| Controls ² | 13 | |
|-----------------------|----|--|
| | | |

Group 1 controls are samples from the region that were negative for VEEV/MADV by all assays.

282 283

284

285

Table 2. Associations between symptoms and biomarkers for group 1 virus infection study population. Clinical symptoms reported in 30 cases for which sex was reported. Statistical significance was determined by a chi-square test.

| | | N | GFAP pg/ml (95% CI) | p-value | UCH-L1 pg/ml (95% CI) | p-value |
|------------|--------|----|-----------------------|---------|------------------------|--------------|
| Sex | | | | | | |
| | Male | 22 | 70.4 (-20.4, 161.2) | 0.482 | 281.4 (143.2, 419.6) | 0.159 |
| | Female | 8 | 38.0 (13.8, 62.2) | | 369.3 (159.0, 579.7) | |
| Age (mean) | | | | | | |
| | 0-10 | 8 | 157.6 (-121.1, 436.2) | 0.881 | 494.8 (109.0, 880.6) | 0.306 |
| | 11-20 | | 25.4 (2.8, 48.0) | | 260.7 (103.5, 418.0) | |
| | 21-30 | | 18.8 (6.7, 30.9) | | 188.3 (134.6, 242.0) | |
| | 31-40 | | 28.4 (-22.6, 79.3) | | 160.7 (76.5, 244.8) | |
| | >41 | 3 | 44.7 (-19.8, 109.3) | | 389.5 (-483.7, 1262.8) | |
| Fever | | | - | · | • | |
| | Yes | 23 | 33.4 (20.9, 46.0) | 0.391 | 295.3 (173.0, 417.6) | 0.902 |
| | No | 7 | 154.8 (-182.0, 491.5) | | 336.3 (7.2, 665.4) | |
| Chills | | | | | | |
| | Yes | 13 | 20.4 (7.0, 33.8) | 0.023 | 222.5 (128.1, 316.9) | 0.277 |
| | No | 17 | 93.4 (-25.0, 211.7) | | 367.9 (182.5, 553.2) | |
| Headache | | | - | · | • | • |
| | Yes | 16 | 22.9 (11.7, 34.1) | 0.135 | 243.5 (161.8, 325.2) | 0.868 |
| | No | 14 | 106.2 (-40.1, 252.5) | | 375.0 (145.9, 604.1) | |
| Arthralgia | | | | | | |
| | Yes | 9 | 19.8 (4.2, 35.5) | 0.08 | 232.1 (69.3, 394.9) | 0.205 |
| | No | | 79.7 (-15.1, 174.5) | | 336.0 (188.5, 483.6) | |
| Myalgia | | | - | • | • | • |
| | Yes | 5 | 16.4 (6.7, 26.1) | 0.303 | 195.1 (125.4, 264.7) | 0.636 |
| | No | 25 | 70.8 (-8.24, 149.9) | | 326.8 (195.1, 458.5) | |
| | | | | | | |
| Nausea | | | - | • | • | . |
| | Yes | 7 | 38.0 (8.9, 67.1) | 0.508 | 328.7 (128.7, 528.7) | 0.447 |
| | No | 23 | 69.0 (-17.6, 155.6) | | 297.6 (159.5, 435.7) | |
| Vomiting | | | - | • | • | • |
| S | Yes | 10 | 40.2 (16.8, 63.6) | 0.482 | 382.5 (118.3, 646.7) | 0.218 |
| | No | | 72.5 (-28.0, 173.0) | | 266.0 (147.9, 384.2) | |

²Group 2 and 3 controls were healthy individuals from the region.

| Abdominal pain | - | | • | • | - |
|-----------------|----|------------------------|-------|------------------------|----------------|
| Yes | 3 | 32.7 (-52.2, 117.6) | 0.863 | 357.1 (-569.6, 1283.7) | 0.809 |
| No | 27 | 65.0 (-8.12, 138.1) | | 299.1 (182.9, 415.2) | |
| Diarrhea | | | • | • | - |
| Yes | 2 | 25.1 (-204.9, 255.1) | 0.678 | 224.6 (-534.6, 983.7) | 0.868 |
| No | 28 | 64.4 (-6.01, 134.7) | | 310.6 (192.4, 428.8) | |
| Lower back pain | - | • | • | • | · - |
| Yes | 1 | 17.1 | 0.862 | 229.8 | 0.773 |
| No | 29 | 623.3 (-4.6, 131.1) | | 307.4 (193.3, 421.6) | |
| Seizures | - | • | • | • | · - |
| Yes | 4 | 302.6 (-417.4, 1022.7) | 0.006 | 665.5 (-329.0, 1659.9) | 0.428 |
| No | 26 | 24.7 (16.3, 33.1) | | 249.4 (179.1, 319.6) | |

Table 3. Associations between symptoms and biomarkers in group 2 bacterial infection (sepsis).

Statistical significance was determined by a chi-square test.

287

288

| | N | GFAP pg/ml (95% CI) | p-value | UCH-L1 pg/ml (95% CI) | P-value |
|----------------|----|-----------------------|---------|-----------------------|----------|
| Sex | | | 0.1490 | | 0.1793 |
| Male | 49 | 27.1 (15.0, 39.2) | | 807.1 (197.7, 1416) | |
| Female | 4 | 49.3 (19.3, 79.4) | | 281.1 (173.4, 388.7) | |
| Age (mean) | | | 0.424 | | 0.9144 |
| 11-20 | 3 | 6.767 (-0.199, 13.7) | | 529.1 (-1298, 2356) | |
| 21-30 | 5 | 82.84 (-10.55, 176.2) | | 2818 (-4244-9880) | |
| 31-40 | 10 | 35.76 (8.028, 63.49) | | 416 (70.84, 761.2) | |
| >41 | 35 | 44.68 (25.41, 63.95) | | 535.1 (233.5, 836.7) | |
| Fever | - | | 0.8704 | | 0.9376 |
| Yes | 36 | 36.02 (25.20. 46.84) | | 352.0 (247.3, 456.7) | |
| No | 13 | 63.46 (6.191, 120.7) | | 883.0 (37.25, 1729) | |
| Headache | | · | 0.0002 | | < 0.0001 |
| Yes | 44 | 428.7 (205.7, 651.8) | | 43.41 (26.21, 60.61) | |
| No | 5 | 42.34 (-28.95,113.6) | | 1058 (-277.8,2393) | |
| Arthralgia | | | 0.5708 | | 0.9455 |
| Yes | 6 | 63.83 (-7.523, 135.2) | | 327.0 (106.2, 547.8) | |
| No | 47 | 41.97 (26.37, 135.2) | | 778.8 (195.3, 1362) | |
| Myalgia | | | 0.1299 | | 0.9811 |
| Yes | 2 | 75.70 (-236.9, 38.3) | | 316.0 (188.7, 2012) | |
| No | 51 | 43.22 (27.7, 58.75) | | 743.8 (206.3, 1281) | |
| Abdominal pain | | • | 0.0793 | | 0.3775 |
| Yes | 23 | 48.89 (31.96, 65.82) | | 944.3 (-199.5, 2088) | |
| No | 30 | 41.04 (16.92, 65.17) | | 561.6 (200.1, 923.1) | |

| Diarrhea | | | 0.3224 | 0.2149 |
|----------|-----------|---|---|--------|
| | Yes No | 36.46 (19.82,53.10) 49.69 (26.65, 72.73) | 376.9 (182.6, 571.3) 957.8 (101.0, 1815) | |
| | | , , | | |


Table 4. Cognitive impairment on follow up in group 3 bacterial infection (sepsis with cognitive assessment).


| MoCA category | Cognitive impairment after discharge percentage (n) | BTI positive at enrollment percentage (n) |
|------------------|---|---|
| Normal (≥26) | 8.2% (5) | 20% (1) |
| Mild (25-18) | 49.2% (30) | 46.7 % (14) |
| Moderate (17-10) | 26.2% (16) | 56.3% (9) |
| Severe (<10) | 16.4% (9) | 100% (9) |

Figures

305

A. Symptoms in Group 1 - Virus Infection









Figure 1. Neurotropic alphavirus exposure cases in Panama from the group 1 virus infection study population. A) (n = 31) were grouped based on antibody reactivity to MADV (n = 7), VEEV (n = 21), and both (n = 3). B) UCH-L1 and GFAP levels (pg/mL) in patient serum (n = 33), where each point represents a single patient: MADV (n = 8), VEEV (n = 22), both (n = 3) and negative (n = 40). Blue points represent patients with seizures (n = 4), and red indicates mortality (n = 1). Comparison of analyte levels in patients grouped by positive or negative for any virus and days of clinical evolution: early (0–7), mid (8–14), late (>15) for C) UCH-L1 and GFAP (pg/mL). Blue points represent patients with seizures (n = 4), and red indicates mortality (n = 1). Statistical significance is based on Mann-Whitney U test vs. negative controls for both viruses.







Figure 2. Severe, hospitalized acute febrile illness cases in Ghana and Cambodia with or without CNS involvement in the group 2 bacterial sepsis cohort. A) Patient-reported symptoms were grouped based on the clinical designation of CNS infection determined by two physicians. B) UCH-L1 and GFAP levels (pg/mL) grouped by CNS, other, or controls. Statistical significance is based on comparison biomarker values at corresponding time points using Mann-Whitney U test vs. healthy controls.



327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

Figure 3. Longitudinal study of group 3 severe bacterial sepsis with cognitive assessment. A) UCH-L1 and GFAP levels (pg/mL) in patient sera from Ghana and Cambodia grouped by study enrollment (day 0) or day 28 post enrollment compared to controls. B) UCH-L1 and GFAP (pg/mL) levels in sera from patients grouped by the average MoCA severity score at discharge and up to six months later. Statistical significance is based on values at corresponding time points using Mann-Whitney U test vs. controls. No MoCA surveys were obtained from controls. C) Comparison of UCH-L1 and GFAP between patients with normal (≥ 26) or impaired (≤ 26) MoCA severity scores at six months post enrollment. D) AUC analysis of the predictive value of GFAP at study enrollment to impaired cognitive function six months later. **Authors' contributions** ML Bartlett, DR Smith, and A Vittor had full access to the study data and take full responsibility for the integrity and accuracy of this analysis. Concept and design: ML Bartlett, DR Smith, A Vittor, R Hayes; Data acquisition, analysis, and interpretation: ML Bartlett, DR Smith, A Vittor, R Hayes, JP Carrera, LF Rivera, C Lezcano-Coba, J Galue, KL Schully, M Gregory, J Brandsma, JG Chenoweth, DV Clark; Laboratory analysis: DR Smith, J Linwood, H Goux, JP Carrera, C Lezcano-Coba and J Galue; Drafting of the manuscript: ML Bartlett, DR Smith; KL Schully, JG Chenoweth, R Hayes, JP Carrera; Statistical analysis: ML Bartlett, A Vittor, J Brandsma. **Funding** The funder was not involved in the study design, analysis, and interpretation of data, writing of the report, or the decision to submit the study results for publication. **Declaration Competing of Interest** The authors of this manuscript have no conflicts of interest to disclose.

Acknowledgments

349

This study was supported by the Defense Threat Reduction Agency under project number

CB10937 to DRS and grant number FID-2021-96 SENACYT to JPC. The views expressed in

this work reflect the results of research conducted by the authors and do not necessarily reflect

the official policy or position of the Department of Defense, the Navy, or the United States

Government. Several of the authors are U.S. Government employees. This work was prepared as

part of their official duties. Title 17, U.S.C., § 105 provides that copyright protection under this

title is not available for any work of the U.S. Government. Title 17 U.S.C., § 101 defines a U.S.

- Government work as work prepared by a military Service member or employee of the U.S.
- 358 Government as part of that person's official duties.

References

- McGill F GM, Bonnett LJ, Geretti AM, Michael BD, Beeching NJ, McKee D, Scarlett P, Hart IJ, Mutton KJ, Jung A, Adan G, Gummery A, Sulaiman WAW, Ennis K, Martin AP, Haycox A, Miller A, Solomon T; UK 2018. Meningitis Study Investigators. Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study. Lancet Infect Dis doi: doi: 10.1016/S1473-3099(18)30245-7.
- Bazarian JJ, Biberthaler P, Welch RD, Lewis LM, Barzo P, Bogner-Flatz V, Gunnar Brolinson P,
 Buki A, Chen JY, Christenson RH, Hack D, Huff JS, Johar S, Jordan JD, Leidel BA, Lindner T,
 Ludington E, Okonkwo DO, Ornato J, Peacock WF, Schmidt K, Tyndall JA, Vossough A, Jagoda
 AS. 2018. Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT
 (ALERT-TBI): a multicentre observational study. Lancet Neurol 17:782-789.
- Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D'Anna L, Huss A, Oeckl P, Ludolph AC, Kuhle
 J, Petzold A, Manley GT, Green AJ, Otto M, Tumani H. 2022. Blood GFAP as an emerging
 biomarker in brain and spinal cord disorders. Nat Rev Neurol 18:158-172.
- Biernacki T, Kokas Z, Sandi D, Füvesi J, Fricska-Nagy Z, Faragó P, Kincses TZ, Klivényi P,
 Bencsik K, Vécsei L. 2022. Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF:
 A Focus on Neurofilaments and Therapeutic Considerations. International journal of molecular sciences 23:3383.
- 5. Kim H, Lee E-J, Lim Y-M, Kim K-K. 2022. Glial Fibrillary Acidic Protein in Blood as a Disease Biomarker of Neuromyelitis Optica Spectrum Disorders. Frontiers in Neurology 13.
- O'Connor A, Abel E, Benedet AL, Poole T, Ashton N, Weston PSJ, Heslegrave AJ, Ryan N, Barker
 S, Polke JM, Blennow K, Zetterberg H, Fox NC. 2023. Plasma GFAP in presymptomatic and
 symptomatic familial Alzheimer's disease: a longitudinal cohort study. J Neurol Neurosurg
 Psychiatry 94:90-92.
- Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, Verberk IMW, Dave P,
 Taddei K, Sohrabi HR, Zetterberg H, Blennow K, Teunissen CE, Vanderstichele HM, Martins RN.

- 2021. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. Translational Psychiatry 11:27.
- 387 8. Gong B, Leznik E. 2007. The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect 20:365-70.
- Cooper J, Stukas S, Hoiland RL, Fergusson NA, Thiara S, Foster D, Mitra A, Stoessl JA, Panenka
 WJ, Sekhon MS, Wellington CL. 2020. Quantification of Neurological Blood-Based Biomarkers
 in Critically Ill Patients With Coronavirus Disease 2019. Crit Care Explor 2:e0238.
- de Menezes EGM, Liu JS, Bowler SA, Giron LB, D'Antoni ML, Shikuma CM, Abdel-Mohsen M,
 Ndhlovu LC, Norris PJ. 2022. Circulating brain-derived extracellular vesicles expressing
 neuroinflammatory markers are associated with HIV-related neurocognitive impairment. Front
 Immunol 13:1033712.
- Carrera JP, Pitti Y, Molares-Martinez JC, Casal E, Pereyra-Elias R, Saenz L, Guerrero I, Galue J,
 Rodriguez-Alvarez F, Jackman C, Pascale JM, Armien B, Weaver SC, Donnelly CA, Vittor AY.
 2020. Clinical and Serological Findings of Madariaga and Venezuelan Equine Encephalitis Viral
 Infections: A Follow-up Study 5 Years After an Outbreak in Panama. Open Forum Infect Dis
 7:ofaa359.
- 401 12. Arrigo NC, Adams AP, Weaver SC. 2010. Evolutionary patterns of eastern equine encephalitis virus in North versus South America suggest ecological differences and taxonomic revision. J Virol 84:1014-25.
- Carrera JP, Forrester N, Wang E, Vittor AY, Haddow AD, López-Vergès S, Abadía I, Castaño E,
 Sosa N, Báez C, Estripeaut D, Díaz Y, Beltrán D, Cisneros J, Cedeño HG, Travassos da Rosa AP,
 Hernandez H, Martínez-Torres AO, Tesh RB, Weaver SC. 2013. Eastern equine encephalitis in
 Latin America. N Engl J Med 369:732-44.
- Carrera JP, Cucunubá ZM, Neira K, Lambert B, Pittí Y, Liscano J, Garzón JL, Beltran D, Collado Mariscal L, Saenz L, Sosa N, Rodriguez-Guzman LD, González P, Lescano AG, Pereyra-Elías R,
 Valderrama A, Weaver SC, Vittor AY, Armién B, Pascale JM, Donnelly CA. 2020. Endemic and
 Epidemic Human Alphavirus Infections in Eastern Panama: An Analysis of Population-Based
 Cross-Sectional Surveys. Am J Trop Med Hyg 103:2429-2437.
- 413 15. Yan X, Yang K, Xiao Q, Hou R, Pan X, Zhu X. 2022. Central role of microglia in sepsis-associated encephalopathy: From mechanism to therapy. Frontiers in Immunology 13.
- 415 16. Mazeraud A, Righy C, Bouchereau E, Benghanem S, Bozza FA, Sharshar T. 2020. Septic-416 Associated Encephalopathy: a Comprehensive Review. Neurotherapeutics 17:392-403.
- Li Y, Ji M, Yang J. 2022. Current Understanding of Long-Term Cognitive Impairment After Sepsis.
 Front Immunol 13:855006.
- Iwashyna TJ, Ely EW, Smith DM, Langa KM. 2010. Long-term cognitive impairment and functional disability among survivors of severe sepsis. Jama 304:1787-94.
- Blair PW, Mehta R, Oppong CK, Tin S, Ko E, Tsalik EL, Chenoweth J, Rozo M, Adams N, Beckett
 C, Woods CW, Striegel DA, Salvador MG, Brandsma J, McKean L, Mahle RE, Hulsey WR,
 Krishnan S, Prouty M, Letizia A, Fox A, Faix D, Lawler JV, Duplessis C, Gregory MG, Vantha T,
 Owusu-Ofori AK, Ansong D, Oduro G, Schully KL, Clark DV. 2023. Screening tools for predicting
 mortality of adults with suspected sepsis: an international sepsis cohort validation study. BMJ Open
 13:e067840.
- 20. Rozo M, Schully KL, Philipson C, Fitkariwala A, Nhim D, Som T, Sieng D, Huot B, Dul S, Gregory
 MJ, Heang V, Vaughn A, Vantha T, Prouty AM, Chao CC, Zhang Z, Belinskaya T, Voegtly LJ,
 Cer RZ, Bishop-Lilly KA, Duplessis C, Lawler JV, Clark DV. 2020. An Observational Study of
 Sepsis in Takeo Province Cambodia: An in-depth examination of pathogens causing severe
 infections. PLoS Negl Trop Dis 14:e0008381.
- Julayanont P, Tangwongchai S, Hemrungrojn S, Tunvirachaisakul C, Phanthumchinda K,
 Hongsawat J, Suwichanarakul P, Thanasirorat S, Nasreddine ZS. 2015. The Montreal Cognitive
 Assessment-Basic: A Screening Tool for Mild Cognitive Impairment in Illiterate and Low Educated Elderly Adults. J Am Geriatr Soc 63:2550-2554.

- Eng LF, Ghirnikar RS, Lee YL. 2000. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 25:1439-51.
- 438 23. Mondello S, Jeromin A, Buki A, Bullock R, Czeiter E, Kovacs N, Barzo P, Schmid K, Tortella F, Wang KK, Hayes RL. 2012. Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. J Neurotrauma 29:1096-104.
- Mondello S, Papa L, Buki A, Bullock MR, Czeiter E, Tortella FC, Wang KK, Hayes RL. 2011.
 Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care 15:R156.
- DeKosky ST, Kochanek PM, Valadka AB, Clark RSB, Chou SH, Au AK, Horvat C, Jha RM, Mannix R, Wisniewski SR, Wintermark M, Rowell SE, Welch RD, Lewis L, House S, Tanzi RE, Smith DR, Vittor AY, Denslow ND, Davis MD, Glushakova OY, Hayes RL. 2021. Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients. J Neurotrauma 38:1-43.
- Teunissen CE, Rohlwink U, Pajkrt D, Naudé PJW. 2022. Biomarkers of Tuberculous Meningitis and Pediatric Human Immunodeficiency Virus on the African Continent. Front Neurol 13:793080.
- 450 27. Rohlwink UK, Figaji AA. 2014. Biomarkers of Brain Injury in Cerebral Infections. Clinical Chemistry 60:823-834.
- 452 28. Grahn A, Hagberg L, Nilsson S, Blennow K, Zetterberg H, Studahl M. 2013. Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections. J Neurol 260:1813-21.
- 454 29. Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D'Anna L, Huss A, Oeckl P, Ludolph AC, Kuhle
 455 J, Petzold A, Manley GT, Green AJ, Otto M, Tumani H. 2022. Blood GFAP as an emerging
 456 biomarker in brain and spinal cord disorders. Nature Reviews Neurology 18:158-172.
- Constant O, Barthelemy J, Nagy A, Salinas S, Simonin Y. 2022. West Nile Virus Neuroinfection in Humans: Peripheral Biomarkers of Neuroinflammation and Neuronal Damage. Viruses 14.
- Zhang LN, Wang XT, Ai YH, Guo QL, Huang L, Liu ZY, Yao B. 2012. Epidemiological features
 and risk factors of sepsis-associated encephalopathy in intensive care unit patients: 2008-2011.
 Chin Med J (Engl) 125:828-31.
- Tang C, Zhou, W., Chen, X. et al. . 2023. Research Progress of Biomarkers of Sepsis-Associated Encephalopathy. Intensive Care Research 3:69-76.
- Wu L, Ai ML, Feng Q, Deng S, Liu ZY, Zhang LN, Ai YH. 2019. Serum glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 for diagnosis of sepsis-associated encephalopathy and outcome prognostication. J Crit Care 52:172-179.
- Yan S, Gao M, Chen H, Jin X, Yang M. 2019. [Expression level of glial fibrillary acidic protein and its clinical significance in patients with sepsensis-associated encephalopathy]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 44:1137-1142.
- de la Monte S, Castro F, Bonilla NJ, Gaskin de Urdaneta A, Hutchins GM. 1985. The systemic pathology of Venezuelan equine encephalitis virus infection in humans. Am J Trop Med Hyg 34:194-202.
- Steele KE, Twenhafel NA. 2010. REVIEW PAPER: pathology of animal models of alphavirus encephalitis. Vet Pathol 47:790-805.
- 475 37. Garen PD, Tsai TF, Powers JM. 1999. Human eastern equine encephalitis: immunohistochemistry and ultrastructure. Mod Pathol 12:646-52.
- Peng BH, Borisevich V, Popov VL, Zacks MA, Estes DM, Campbell GA, Paessler S. 2013.
 Production of IL-8, IL-17, IFN-gamma and IP-10 in human astrocytes correlates with alphavirus attenuation. Vet Microbiol 163:223-34.
- Schoneboom BA, Fultz MJ, Miller TH, McKinney LC, Grieder FB. 1999. Astrocytes as targets for Venezuelan equine encephalitis virus infection. J Neurovirol 5:342-54.
- 482 40. Ronca SE, Dineley KT, Paessler S. 2016. Neurological Sequelae Resulting from Encephalitic Alphavirus Infection. Front Microbiol 7:959.